UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fasting-mimicking diet plus chemotherapy in breast cancer treatment

Nature communications, 2020-08, Vol.11 (1), p.4274-4274, Article 4274

2020

Volltextzugriff (PDF)

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients

Clinical cancer research, 2017-08, Vol.23 (15), p.4312-4322

2017

Volltextzugriff (PDF)

Risk assessment of thromboembolic events in hospitalized cancer patients

Scientific reports, 2021-09, Vol.11 (1), p.18200-10, Article 18200

2021

Volltextzugriff (PDF)

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications

Breast cancer research : BCR, 2020-04, Vol.22 (1), p.33-33, Article 33

2020

Volltextzugriff (PDF)

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

Cells (Basel, Switzerland), 2020-12, Vol.9 (12), p.2644

2020

Volltextzugriff (PDF)

Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications

Therapeutic Advances in Medical Oncology, 2022-03, Vol.14, p.17588359221079123-17588359221079123

2022

Volltextzugriff (PDF)

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231165978-17588359231165978

2023

Volltextzugriff (PDF)

Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report

Tumori, 2021-12, Vol.107 (6), p.NP15-NP19

2021

Volltextzugriff (PDF)

Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin

Frontiers in oncology, 2022-08, Vol.12

2022

Volltextzugriff (PDF)

Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231204857-17588359231204857

2023

Volltextzugriff (PDF)

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211006960-17588359211006960

2021

Volltextzugriff (PDF)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

NPJ breast cancer, 2023-04, Vol.9 (1), p.27-27, Article 27

2023

Volltextzugriff (PDF)

Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer

Current opinion in oncology, 2023-11, Vol.35 (6), p.491-499

2023

Volltextzugriff (PDF)

Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920970081-1758835920970081

2020

Volltextzugriff (PDF)

Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence

Cell metabolism, 2024-08, Vol.36 (8), p.1644-1667

2024

Volltextzugriff (PDF)

Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial

European journal of cancer (1990), 2022-09, Vol.172, p.300-310

2022

Volltextzugriff (PDF)

Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

Cancer discovery, 2022-01, Vol.12 (1), p.90-107

2022

Volltextzugriff (PDF)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

Cancers, 2021-04, Vol.13 (8), p.1964

2021

Volltextzugriff (PDF)

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness

Cancers, 2021-09, Vol.13 (19), p.4778

2021

Volltextzugriff (PDF)

Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer

Cancer letters, 2021-07, Vol.511, p.77-87

2021

Volltextzugriff (PDF)

Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7), p.1133-1148

2024

Volltextzugriff (PDF)

Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities

Critical reviews in oncology/hematology, 2023-10, Vol.190, p.104109, Article 104109

2023

Volltextzugriff (PDF)

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab

JNCI : Journal of the National Cancer Institute, 2022-12, Vol.114 (12), p.1720-1727

2022

Volltextzugriff (PDF)

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

Cancers, 2019-12, Vol.12 (1), p.67

2019

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(56)

Publikationsform

Sprache

Englisch
(61)
Italienisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fasting-mimicking diet plus chemotherapy in breast cancer treatment

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients

Risk assessment of thromboembolic events in hospitalized cancer patients

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report

Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin

Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer

Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis

Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence

Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial

Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness

Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer

Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia

Adding fasting‐mimicking diet to first‐line carboplatin‐based chemotherapy is associated with better overall survival in advanced triple‐negative breast cancer patients: A subanalysis of the NCT03340935 trial

Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

Suchergebnisse filtern